You have requested access to member-only content.
Interpreting guidance from CMS' 340B FAQs
CMS' 340B FAQ reviews modifiers -JG (drug or biological acquired with 340B drug pricing program discount) and -TB (drug or biological acquired with 340B drug pricing program discount, reported for informational purposes) and requires 340B hospitals to report modifiers even on drugs that are not subject to the discount policy.
This is an excerpt from member-only content. Please log in or become a member.
Log in to access this content:
Unable to log in?
Click here to reset your password or unlock your account.
Forgot your username?
Contact customer care at customerservice@hcpro.com or call 800-650-6787, between 8 AM - 5 PM CT
Not a member? Join now!
Revenue Cycle Advisor is the key to your organization's Medicare regulatory news and education. It combines all of HCPro's Medicare regulatory and reimbursement resources into one handy and easy-to-access portal. News is not just repeated from other sources. It is analyzed by our Medicare experts so professionals can comprehend any new rule updates thoroughly.
For questions and support, please call customer service: 800-650-6787.
Try before you buy with our FREE samples!